Description
Cas:300809-71-6
Product Information:
DUN09716 is KRAS inhibitor with potential antitumor activity. DUN09716 was reported inn patent US 9884046. DUN09716 has CAS# 300809-71-6, no formal name. For the convenience of scientific communication, we named it as DUN09716 (combined from Inchi key plus CAS#) according to Hodoodo Chemical Nomenclature
Chemical Formula: C13H9ClN2S2
Exact Mass: 291.9896
Molecular Weight: 292.799
Elemental Analysis: C, 53.33; H, 3.10; Cl, 12.11; N, 9.57; S, 21.90
Synonym:
DUN-09716
DUN 09716
Chemical Name:
4-[(Benzo[d]thiazol-2-yl)thio]-3-chloroaniline
InChi Key:
DTSNLMOLTVGCGZ-UHFFFAOYSA-N
InChi Code:
InChI=1S/C13H9ClN2S2/c14-9-7-8(15)5-6-11(9)17-13-16-10-3-1-2-4-12(10)18-13/h1-7H,15H2
Smiles Code:
NC1=CC=C(SC2=NC3=CC=CC=C3S2)C(Cl)=C1
Technical Data:
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
In Vitro:
KRAS inhibitor-9 bound to KRASG12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity of -5.38, -5.41, and -3.97 kcal/mol, respectively.
KRAS inhibitor-9 (0-100 μM) shows strong inhibition selectivity in NSCLC cells with IC50s ranging from 39.56 to 66.02 μM for H2122, H358 and H460 cells (at 72 hours).
KRAS inhibitor-9 (0-100 μM; 24 hours) blocks GTP-KRAS formation in H2122, H358 and H460 cells.
KRAS inhibitor-9 (25-100 μM; 48 hours) inhibits the activation of KRAS downstream signaling pathway.
KRAS inhibitor-9 (0-100 μM; 24-72 hours) induces cell cycle arrest and apoptosis in NSCLC.
References:
-
Xie C, et al. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. Front Pharmacol. 2017;8:823. Published 2017 Nov 14.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.